1. Basic Information
Disease Protected Against
Poliomyelitis (Polio) is a enteroviral infection that can cause irreversible acute flaccid paralysis in ~1% of infections. Before vaccination, polio caused widespread epidemics. The U.S. experienced its peak epidemic in 1952 with >21,000 paralytic cases. Polio has been declared eliminated in the Americas (1994), but wild poliovirus type 1 remains endemic in Afghanistan and Pakistan. Circulating vaccine-derived polioviruses (cVDPV) from OPV use in other countries represent an ongoing global eradication challenge.
CDC Schedule (U.S., 2025)
| Dose | Age |
|---|---|
| Dose 1 | 2 months |
| Dose 2 | 4 months |
| Dose 3 | 6–18 months |
| Dose 4 (booster) | 4–6 years |
Source: CDC ACIP, 2025 schedule. IPV is given as a standalone vaccine (IPOL®) or as part of combination vaccines (Kinrix, Quadracel, Pediarix, Pentacel, VAXELIS).
2. Pre-Licensure Clinical Trial Data
The current enhanced-potency IPV (IPOL, Sanofi) was licensed in 1987 based on immunogenicity trials. Prior IPV formulations date back to the Salk vaccine (1955). The enhanced IPV formulation was developed to improve immunogenicity.
| Metric | Data |
|---|---|
| Pre-licensure safety population | ~2,000+ children; immunogenicity studies in ~1,500 |
| Seroconversion (3-dose series) | ~99–100% for all 3 poliovirus types |
| Most common reactions | Injection site pain (~5–15%), erythema (~2–5%), fever (~5–10%) |
IPV has minimal reactogenicity compared to many other childhood vaccines. This is one of the least reactogenic vaccines on the pediatric schedule.
Key Limitation
IPV produces excellent humoral immunity (prevents paralysis) but induces less mucosal (intestinal) immunity than OPV. This means IPV-vaccinated individuals can still be asymptomatically infected with poliovirus and shed it in stool, though they are protected from paralysis. This is relevant for global eradication efforts.
3. Post-Licensure Safety Data
IPV has an excellent post-licensure safety record with >35 years of U.S. data. VSD and VAERS surveillance have not identified unexpected safety signals. The switch from OPV to IPV in 2000 eliminated the risk of VAPP (vaccine-associated paralytic polio), which was the primary safety concern with the prior OPV formulation. IOM (2012) did not identify safety concerns specific to IPV.
⚠ Critical Caveat
VAERS data represent unverified reports. A report to VAERS does not mean the vaccine caused the event.
4. Documented Adverse Events
▶ Strong Evidence
- Injection site reactions: Mild pain (5–15%), erythema (2–5%). Strong
- Low-grade fever: 5–10%. Strong
- Anaphylaxis: Extremely rare (~1 per million doses). Strong
▶ Historical Note (OPV — No Longer Used in U.S.)
The OPV was associated with VAPP at a rate of ~1 per 2.4 million doses (approximately 8–10 cases/year in the U.S. when OPV was used). This was the reason for the U.S. switch to IPV in 2000. Strong (causal for OPV; not applicable to IPV)
5. Disease Prevention Benefits
| Metric | Pre-Vaccine Era | Post-Vaccine Era (U.S.) |
|---|---|---|
| Paralytic polio (annual) | ~21,000 cases (1952 peak) | 0 wild-type cases since 1979; last U.S. case 1979 (imported 1993) |
| Global polio (1988 vs. 2023) | ~350,000 cases/year | <1,000 cases/year (>99.9% reduction) |
A 2022 case of paralytic polio in an unvaccinated individual in Rockland County, NY, and detection of poliovirus in wastewater, served as a reminder of ongoing risk.
6. Evidence Summary
IPV is one of the safest and most effective vaccines in the pediatric schedule. The safety record is extensive (>35 years), and no significant post-licensure safety signals have been identified. The primary historical safety concern (VAPP) was specific to OPV and was eliminated by the IPV switch. Evidence limitations relate primarily to the modest size of pre-licensure trials (by modern standards) and the difficulty of isolating IPV-specific safety signals when most doses are given as combination vaccines.
7. Key References
- IOM. Adverse Effects of Vaccines: Evidence and Causality. National Academies Press; 2012.
- CDC. Pink Book — Poliomyelitis chapter. cdc.gov/pinkbook
- Global Polio Eradication Initiative (GPEI). polioeradication.org
- CDC. VSD. cdc.gov/vaccine-safety/about/vsd.html
- CDC/FDA. VAERS. vaers.hhs.gov